This is an aggregated industry headline. Read the full story at FiercePharma →
Novo CEO sees advantages in souping up NYSE listing: report
The Ozempic and Wegovy maker's CEO said he's open to a direct listing of Novo's shares on the New York Stock Exchange, but no such transition is currently underway.
By FiercePharma
· Sep 24, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
The government released 2027 Medicare Advantage quality ratings, and early coverage singled out Humana as the …
The WeekPharmaceutical Technology ↗
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist ra…
The WeekAJMC ↗
Using Complement Inhibitors in GA Comes With Pros and Cons…